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Abstract  
Introduction: Tumour-induced osteomalacia (TIO) is a rare paraneoplastic syndrome 
characterised by refractory hypophosphataemia mediated by fibroblast growth factor 
23 (FGF23) produced by small, mesenchymal tumours. Herein, we report a hitherto 
unrecognised case of TIO whose hypophosphataemic symptoms suddenly worsened 
following inadvertent use of teriparatide.  
Case presentation: A 45-year-old man presented with lower limb proximal 
myopathy for the past 1,5 years. Six months earlier he suffered bilateral femoral neck 
fractures following a trivial trauma for which he underwent bilateral total hip 
replacement. He was started on teriparatide to promote fracture healing without prior 
assessment of serum phosphate levels. After one month his myopathy rapidly 
worsened, and within six months he became completely bedbound. Examination 
revealed reduced lower limb proximal muscle power with intact deep tendon reflexes. 
Biochemical investigations showed hypophosphataemia, normocalcaemia, elevated 
alkaline phosphatase, and low tubular reabsorption of phosphate corrected for 
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glomerular filtration rate (TmP/GFR). Serum FGF23 was elevated with 
inappropriately low 1, 25-dihydroxy vitamin D. 68Ga-DOTATATE PET-CT showed a 
small tracer-avid soft tissue lesion in the left thigh. The lesion was excised, and 
histopathology showed phosphaturic mesenchymal tumour. Phosphate levels rose and 
FGF23 levels fell post-operatively. At three months’ follow-up, he is able to stand and 
walk by himself. His serum phosphate has normalised.  
Conclusion: Hypophosphataemia with teriparatide use is an oddity. Unexplained 
hypophosphataemia in a patient on teriparatide should make the physician think of 
hypophosphataemic osteomalacia. Serum phosphate levels should be estimated prior 
to teriparatide use and its use refrained in patients with unexplained 
hypophosphataemia.  
Keywords: tumour-induced osteomalacia; teriparatide; hypophosphataemia; fragility 
fracture 
 
Case presentation 
A 45-year-old man presented with lower limb proximal muscle weakness that had 
begun 1.5 years back. He developed bilateral fracture neck femora following a trivial 
fall onto the ground one year ago (Fig. 1A). He underwent bilateral hip replacement 
for the same at a private healthcare facility. He was discharged on calcium and 
vitamin D supplements along with recombinant human parathyroid hormone 
(rhPTH/teriparatide) at a dose of 20 micrograms once daily to promote fracture 
healing. After one month of teriparatide therapy, his symptoms aggravated. His lower 
limb muscle power declined, soon requiring support to stand up and walk. This was 
associated with marked bony pain over the lower limbs. Six months later he became 
bedbound. The patient stopped taking teriparatide and subsequently presented to our 
institute. A review of previous investigations (performed at a private hospital) 
revealed serum calcium 9.2 mg/dL (range: 8.6–10.4), total alkaline phosphatase 
(ALP) 672 IU/L (range:74–138), and 25-hydroxyvitamin D 18 ng/mL. However, a 
serum phosphorous report was not available. Histopathology of the excised femoral 
heads was reported as having osteomalacia. 
Physical examination revealed lower limb proximal myopathy. Distal muscle power, 
deep tendon reflexes and sensory system were intact. Biochemical investigations 
revealed hypophosphataemia (0.9–1.1 mg/dL, range: 2.8–4.5), elevated ALP (790 
IU/L, range: 78–128), and vitamin D sufficiency. Urinalysis revealed renal phosphate 
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wasting with low tubular reabsorption of phosphate corrected for glomerular filtration 
rate (TmP/GFR = 0.409 mg/dL, age-specific range: 2.8–4.2). Serum FGF23 level 
(measured by C-terminal ELISA, Quidel, Immutopics) was elevated at 513.8 RU/mL 
(range: 0.0–150.0) with inappropriately low 1, 25-dihydroxyvitamin D (24.2 pg/mL, 
range: 19.9–79.3). Somatostatin-receptor (SSTR)-based scintigraphy with 68Ga-
DOTATATE PET-CT showed a 1 cm × 1 cm tracer-avid soft tissue lesion in the 
medial aspect of the left thigh (Fig. 1B). It was concordant on ultrasonography. The 
lesion was excised with a wide resection margin. Serum phosphate levels rose, 
reaching 2.8 mg/dL on the fourth post-operative day. Simultaneously, serum FGF23 
levels fell to 103.8 RU/mL. Histopathology of the excised lesion was suggestive of 
phosphaturic mesenchymal tumour. At two months follow-up, there has been a 
marked symptomatic improvement with the patient able to stand and walk on his own. 
His serum phosphate has increased to 3.8 mg/dL and his ALP level has come down to 
288 IU/L.  
 
Discussion 
Tumour-induced osteomalacia is a rare paraneoplastic syndrome characterised by 
refractory hypophosphataemia and is usually associated with benign mesenchymal 
soft-tissue tumours that produce FGF23 [1, 2]. FGF23, acting via FGF receptor 1 
(FGFR1) and co-receptor α-klotho on renal proximal tubules promotes internalisation 
of sodium-phosphate co-transporters (NaPi) from the luminal membrane to the 
cytoplasm, thereby reducing tubular phosphate reabsorption and causing phosphaturia 
[3]. In addition, FGF23 also reduces renal mRNA and protein levels of NaPi-2a co-
transporters [4]. Similarly, PTH, acting via G-protein-coupled PTH receptor 1 
(PTHR1), increases cAMP in proximal tubular cells, reducing luminal expression of 
NaPi, culminating in phosphaturia. In fact, the internalisation of NaPi co-transporters 
seems to be faster and more effective under the effect of PTH as compared to FGF23 
[4, 5]. In addition, PTH, either directly or via increase in serum 1,25-
dihydroxyvitamin D, tends to increase FGF23 secretion from bone cells [5, 6]. Thus, 
an excess of endogenous circulating PTH is expected to increase the serum levels of 
FGF23 as well as potentiate its action at the renal level. The same should hold true 
with exogenously administered hPTH as well. Studies have shown that infusion of 
hPTH (1–34) in healthy human volunteers leads to a rise in circulating FGF23 levels, 
mostly mediated by a rise a serum 1,25-dihydroxyvitamin D levels. Thus, a milieu, 
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wherein PTH and FGF23 are both in excess will aggravate hypophosphataemia. This 
phenomenon is exemplified in our patient where the hypophosphataemic symptoms 
were exacerbated on inadvertently adding rhPTH in a state of underlying FGF23 
excess.  
Tumour-induced osteomalacia must have been the underlying cause of the fragility 
fractures involving the neck of the femora; however, an attempt to promote fracture 
healing with teriparatide acted as fuel to the fire, aggravating hypophosphataemia.  
Although transient hypercalcaemia is a known adverse effect of teriparatide therapy, 
hypophosphataemia is extremely rare [7]. Refractory hypophosphataemia in a patient 
on teriparatide should make the clinician think of TIO. The serum phosphate level of 
the index patient was not assessed before initiating teriparatide. With widespread 
availability of teriparatide and innumerable biosimilars on the market, there is a 
temptation among unwary physicians and surgeons to prescribe rhPTH for indications 
that are not approved by conventional guidelines. Such a practice should be 
condemned in routine clinical practice. In addition, physicians planning to prescribe 
teriparatide should beforehand order a basic biochemical panel that must include a 
minimum of serum calcium, phosphorous, ALP, and creatinine and refrain from its 
use in patients with unexplained hypophosphataemia.  
 
Conflicts of interest 
The authors declare that they have no conflicts of interest. 
Funding sources 
None. 
Patient consent 
Informed, written consent was obtained from the patient. 
Acknowledgements 
None. 
 
References 
1. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007; 18(6): 
1637–1647, doi: 10.1681/ASN.2007010068, indexed in Pubmed: 17494882. 
2. Pal R, Bhadada SK, Shingare A, et al. Tumor-induced osteomalacia: experience from three 
tertiary care centres In India. Endocr Connect. 2019 [Epub ahead of print], doi: 10.1530/EC-18-
0552, indexed in Pubmed: 30726771. 
 5 
3. Minisola S, Peacock M, Fukumoto S, et al. Tumour-induced osteomalacia. Nat Rev Dis 
Primers. 2017; 3: 17044, doi: 10.1038/nrdp.2017.44, indexed in Pubmed: 28703220. 
4. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D 
metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3): 429–435, 
doi: 10.1359/JBMR.0301264, indexed in Pubmed: 15040831. 
5. Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord. 2015; 16(2): 
165–174, doi: 10.1007/s11154-015-9318-z, indexed in Pubmed: 26296372. 
6. Lanske B, Razzaque MS. Molecular interactions of FGF23 and PTH in phosphate regulation. 
Kidney Int. 2014; 86(6): 1072–1074, doi: 10.1038/ki.2014.316, indexed in Pubmed: 25427080. 
7. Hajime M, Okada Y, Mori H, et al. A case of teriparatide-induced severe hypophosphatemia 
and hypercalcemia. J Bone Miner Metab. 2014; 32(5): 601–604, doi: 10.1007/s00774-014-
0564-z, indexed in Pubmed: 24553859. 
 
 
Figure 1. A. Antero-posterior radiograph of the pelvis showing bilateral fracture neck 
femora (marked in black arrows). B. Fused 68Ga-DOTATATE PET-CT image 
showing a 1 cm × 1 cm tracer-avid soft tissue lesion (marked in blue arrow) in the 
subcutaneous plane of the medial aspect of the left thigh region just anterior to the 
belly of the gracilis muscle [maximum standardised uptake value (SUVmax) of 12.8] 
 
